Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT07821411
A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS). This is a non-interventional study using administrative claims data available in Germany and Japan.
Official title: Real-World Outcomes of Ofatumumab: Relapse Rates, Disease Progression, and Treatment Patterns in Germany and Japan
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
5000
Start Date
2026-07-31
Completion Date
2026-09-30
Last Updated
2026-09-15
Healthy Volunteers
No
Conditions
Locations (1)
Novartis
Basel, Switzerland